XORTX Therapeutics Raises $1.1 Million in Direct Offering Amid Nasdaq Compliance Extension
XORTX Therapeutics has secured $1.1 million in a direct offering to support its development of therapies for metabolic and cardiovascular disorders, while also addressing a Nasdaq bid-price compliance issue with a 180-day extension.
3 minutes to read